Sarah Bolander, DMSc, MMS, PA-C, DFAAPA
The purpose of this article is to review the effectiveness and safety of ticagrelor in the prevention of recurrent stroke in patients who are diagnosed with ischemic stroke and/or transient ischemic attack (TIA). Ticagrelor is an antiplatelet therapy. It works by making the platelet less sticky, hence preventing clot formation. Ticagrelor is believed to have a stronger antiplatelet effect, a quicker onset of action, and can be more potent compared to clopidogrel or aspirin. Current research does not show strong support for ticagrelor’s effect in decreasing bleeding risk; however, it does support ticagrelor’s effect in lowering the risk of recurrent stroke and/or death when combined with aspirin. Therefore, given the potentially life-threatening adverse effect of ticagrelor (ie bleeding), further research becomes warranted to establish if ticagrelor is indeed the optimal option in preventing recurrent strokes while enhancing the quality of life of the patients.
Ohi H. Ticagrelor in Preventing Recurrent Stroke. Lynchburg Journal of Medical Science. 2022; 4(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.